Healthcare, competitiveness, innovation and simplification
News
20 May 2026
Healthcare, simplification

Europe’s life sciences sector sits at the heart of the EU’s competitiveness agenda. It supports advanced manufacturing and helps bring new treatments and technologies to patients. Yet companies deciding where to invest need a regulatory environment that is predictable and open to global cooperation. 

The European Commission’s work on the Biotech Act and the targeted revision of the Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) offers an opportunity to improve that environment. Both files can help make Europe a stronger location for life sciences investment. 

The EU should use this moment to build a framework that keeps pace with scientific progress. That means faster and clearer procedures. It also means better use of data and intellectual property rules that recognise the realities of global supply chains. 

Biotechnology

The Biotech Act can strengthen Europe’s biotechnology ecosystem by making regulatory pathways more efficient and improving coordination at EU level. It can also support the responsible use of data and AI in research and manufacturing. These improvements will only have an impact if they are implemented consistently and work in practice for companies operating across several Member States.

Europe also needs incentives that match the scale and risk of biotechnology investment. A strengthened supplementary protection certificate extension would help ensure that faster procedures lead to more research, clinical activity and manufacturing in Europe. The framework should remain science based and open to international cooperation, while supporting diverse supply chains and the skills needed for long-term competitiveness.

Medical technology

The targeted revision of the MDR and IVDR is a welcome step toward a more workable medical technology framework. It would replace rigid certification cycles with risk-based reviews and make certain post-certification changes easier to manage. By recognising real-world evidence and creating clearer routes for breakthrough devices, the proposal would strengthen Europe’s position as a launch market for medical technologies.

Further changes would give companies greater certainty and better support innovation. Policymakers should clarify the rules for drug device combination products and ensure that reprocessing rules keep patient safety at the centre. Labelling changes should remain subject to appropriate oversight. Health institution exemptions should also be carefully balanced so they do not weaken patient safeguards or distort competition.

The MDR and IVDR must also align properly with wider EU legislation, including the AI Act and cybersecurity rules. Clearer timelines and a single reporting approach would help avoid duplication. A more flexible framework would make Europe a more attractive place to launch medical technologies and improve patient access across the EU.

Related items

News
12 Nov 2026

Keeping Europe open and competitive with our Executive Council

Predictability in EU-US relations and Europe’s competitiveness agenda, from simplification to European preference, were centre stage during our Executive Council Fall Plenary on Monday, 9 and Tuesday, 10 November. Our senior business leaders met with EU, US, Canadian and Member State policymakers, as well as industry and think-tank leaders, to discuss the pressures shaping investment decisions in Europe.

The group engaged with the following: Nerijus Aleksiejūnas, Permanent Representative of Lithuania to the European Union; Enrico Letta, President of the Jacques Delors Institute; Roxana Mînzatu, Executive Vice-President for Social Rights and Skills, Quality Jobs and Preparedness, European Commission; Andrew Puzder, Ambassador of the United States to the European Union; Jessika Roswall, European Commissioner for Environment, Water Resilience and a Competitive Circular Economy; Sir Jonathan Symonds, President of the European Round Table for Industry and Chair of GSK and Jonathan Wilkinson, Ambassador of Canada to the European Union. 

Throughout the two days, exchanges explored how to maintain momentum on Single Market integration, deliver meaningful regulatory simplification and strengthen the role of industry in developing skills and creating quality jobs. Discussions also touched on the changing international trade landscape, the importance of EU-US cooperation and the priorities that will shape the upcoming Lithuanian Presidency of the Council of the EU.

Learn more about our Executive Council here. 

Simplification
Transatlantic
Read more
Read more about Keeping Europe open and competitive with our Executive Council
News
3 Nov 2026

A compass for better care

Beating cancer is one fight; protecting the heart through treatment is another. Heart-related complications are now the second leading cause of death among cancer survivors, and with diagnoses in Europe expected to rise 18% by 2040, the challenge will only grow. COMPASS, a €50.5 million initiative bringing together more than 60 partners, is building an AI-powered system that helps flag cardiotoxicity risk early and personalise care, so oncologists and cardiologists can act sooner and keep cancer treatment on track. GE HealthCare leads the industry side of the work, helping turn the research into everyday clinical practice across Europe. Read the full story on Invested in Europe.

Healthcare
Read more
Read more about A compass for better care
Position Paper
22 Oct 2026

Industry calls for repeal of the SCIP database

AmCham EU has joined over 30 industry associations in calling on EU co-legislators to confirm the repeal of the Substances of Concern In articles as such or in complex objects (Products) (SCIP) database, as proposed in the Environmental Omnibus. SCIP costs companies around €225 million a year, yet its intended users, recyclers, barely use it. The Commission itself acknowledges that waste operators find the data unusable and most companies lack the resources to maintain millions of notifications. Repeal would remove a disproportionate reporting layer while keeping obligations for suppliers to inform customers about substances of very high concern. Any future approach should build on existing obligations, not add new ones.

Environment
Simplification
Read more
Read more about Industry calls for repeal of the SCIP database